Of the two heart valve surgeries Janice Smith has had at OhioHealth Mansfield Hospital, the second was much easier for her. "I had a good experience both times," the 86-year-old said. "It's just that ...

At 6 years, transcatheter aortic valve replacement (TAVR) appears to rival surgery for major adverse events in low-risk patients with severe aortic stenosis, but it may come at the cost of more ...

At ACC 2026, retrospective results were presented demonstrating the possibility of using pharmacotherapies for patients after ...

Several cardiology organizations have issued an expert consensus document on the use of transcatheter aortic valve replacement for patients with aortic valvular stenosis, which was recently approved ...

At the annual meeting of the European Society of Cardiology (ESC), being held this weekend in Madrid, new cardiac care guidelines call for a more uniform, simplified and accessible approach to ...

The use of transcatheter aortic valve replacement (TAVR) increased among healthier, lower-risk patients younger than 65 between 2012 and 2024, despite a lack of randomized data on this patient ...

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic valve stenosis. With proven safety and efficacy, TAVR has become a standard therapeutic alternative to surgical ...

Please provide your email address to receive an email when new articles are posted on . TAVR did not improve a composite of clinical endpoints in patients with moderate aortic stenosis and HFrEF.

Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.